News

Company News & Events

Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting

12 September 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

• World renowned Key Opinion Leader Dr. Xavier Montalban to join Oryzon’s Scientific Advisory Board

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today it will present efficacy data on its proprietary oral epigenetic drug ORY-2001 in a preclinical multiple sclerosis (MS) animal model.

Click here to see the full Press Release

Posted In: 
Investors
News

Share this story